Publication | Open Access
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
40
Citations
5
References
2020
Year
NCT01403974; NCT01317420.
| Year | Citations | |
|---|---|---|
Page 1
Page 1